Related Experiment Video
Updated: Sep 22, 2026
Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma
Published on: March 3, 2023
Experimental investigation and network pharmacology-based analysis of the anticancer mechanisms of Fei Jin Sheng
Zhen Yan1, Qian Li2, Jian-Xiang Chen2
1Department of Gerontology, The Affiliated Hospital of Hangzhou Normal University, Hangzhou, 310000, Zhejiang, China.
Abstract:
This study involves the evaluation of the Fei Jin Sheng formula (FJS), a well-established traditional Chinese medicine (TCM) treatment for non-small cell lung cancer (NSCLC), aiming to address the heightened mortality rates associated with this form of lung cancer. By examining its multi-targeted routes and activities in vivo, we hope to clarify its complex molecular mechanisms. Liquid chromatography-tandem mass spectrometry and network pharmacology were used to identify FJS components and targets. Using organ histology and bi-weekly weight assessments of tumors and bodies and Lewis tumor model tumors, FJS efficacy and safety were assessed, while immunohistochemistry of tumor tissues was used to elucidate anti-tumor mechanisms. Based on research that had been previously conducted, FJS controls over 30 pathways and targets 15 critical proteins, including the MAPK pathway, in treating NSCLC. In vivo studies demonstrate that FJS reduces tumor proliferation by decreasing expression of ERK1/2, p-ERK1/2, MEK1/2, and p-MEK1/2, without affecting the structure of the liver, spleen, or kidney in mice. FJS is non-toxic and has the potential to treat NSCLC in vivo by inhibiting the MAPK signaling pathway.
Insights
The traditional Chinese medicine Fei Jin Sheng formula (FJS) shows potential in treating non-small cell lung cancer (NSCLC) by inhibiting the MAPK pathway. In vivo studies confirm FJS is non-toxic and reduces tumor proliferation without adverse effects.
Area of Science:
- Integrative Oncology
- Traditional Chinese Medicine
- Molecular Pharmacology
Background:
- Non-small cell lung cancer (NSCLC) has high mortality rates, necessitating novel therapeutic strategies.
- Traditional Chinese Medicine (TCM) offers potential treatments, such as the Fei Jin Sheng formula (FJS), with complex mechanisms.
- Understanding the molecular pathways targeted by FJS is crucial for its clinical application in NSCLC.
Purpose of the Study:
- To evaluate the efficacy and safety of the Fei Jin Sheng formula (FJS) for non-small cell lung cancer (NSCLC).
- To elucidate the molecular mechanisms underlying FJS's anti-tumor activity in vivo.
- To identify key molecular targets and pathways modulated by FJS in NSCLC treatment.
Main Methods:
- Liquid chromatography-tandem mass spectrometry and network pharmacology were employed to identify FJS components and targets.
- In vivo studies utilized a Lewis tumor model to assess FJS efficacy and safety, including tumor and body weight monitoring.
- Immunohistochemistry of tumor tissues was performed to investigate anti-tumor mechanisms, focusing on the MAPK signaling pathway.
Main Results:
- FJS demonstrated efficacy in reducing tumor proliferation in the Lewis tumor model.
- Key molecular targets within the MAPK pathway, including ERK1/2 and MEK1/2, were found to be downregulated by FJS treatment.
- Organ histology confirmed that FJS treatment did not adversely affect the structure of the liver, spleen, or kidney in mice, indicating a favorable safety profile.
Conclusions:
- The Fei Jin Sheng formula (FJS) is a non-toxic traditional Chinese medicine with potential for treating non-small cell lung cancer (NSCLC) in vivo.
- FJS exerts its anti-tumor effects primarily through the inhibition of the MAPK signaling pathway.
- Further research into FJS could lead to novel therapeutic strategies for NSCLC, leveraging its multi-targeted molecular actions.
